Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints

The meeting continued with representatives from active, observational studies sharing how biomarker and clinical data contribute to our understanding of amyloid beta, tau, and other pathologies, and subject matter experts who presented modeling data to advance AD treatment strategies. [...]biomarker...

Full description

Saved in:
Bibliographic Details
Published in:Alzheimer's & dementia : translational research & clinical interventions 2022, Vol.8 (1), p.e12361-n/a
Main Authors: Petersen, Ronald C., Graf, Ana, Carrillo, Maria C., Weber, Christopher J.
Format: Article
Language:English
Subjects:
Alzheimer's disease
Animal cognition
Biomarkers
Clinical trials
Dementia
Monoclonal antibodies
Neurodegeneration
Observational studies
Pathophysiology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The meeting continued with representatives from active, observational studies sharing how biomarker and clinical data contribute to our understanding of amyloid beta, tau, and other pathologies, and subject matter experts who presented modeling data to advance AD treatment strategies. [...]biomarker changes in amyloid beta are reasonably likely to predict changes in clinical outcome measures and should be considered meaningful to all patients who may potentially benefit from these treatments. There is much work to be done, and the scientific community needs to stay focused on defining those tools most appropriate to capture these changes, the populations best suited to enroll in clinical trials, and defining our expectations of what changes can be expected over a particular interval of time. CONFLICTS OF INTEREST R.P. is a full-time employee of Mayo Foundation for Education and Research and a consultant for Biogen, Inc., Roche, Inc., Merck, Inc., Genentech Inc. (DSMB), and Eisai, Inc. A.G. is a full-time employee of NovartisPharma AG. M.C.C., C.J.W. are full-time employees of the Alzheimer's Association.
ISSN:2352-8737
2352-8737
DOI:10.1002/trc2.12361